It has been studied for its remarkable healing properties in various tissues, including the gut
The Bridge program rules dictate that if a patient has a BMI of 35, but their sleep apnea crosses the threshold from mild to moderate, they are disqualified from gaining access to a GLP-1 through the Bridge initiative
Study author Sun H Kim, MD, MS, Associate Professor of Medicine in the Division of Endocrinology, Gerontology, and Metabolism at Stanford, summarized the findings to to Medical News Today , saying: We found that semaglutide compared to other weight loss medications, including another GLP-1 medication called dulaglutide, reduced risk of future fractures despite being associated with greater weight loss. Overall, semaglutide was linked to a bigger decrease in BMI
Without glutathione, our cells cannot perform their activities optimally
GLP-1 RAs are very effective at lowering blood sugar levels both after meals and during fasting
The absence of published, large-scale human trials means that its use in clinical practice remains on the frontier of peptide medicine